Keeping those telomeres short! an innovative intratumoral long-term drug delivery system

详细信息    查看全文

• 作者：B. H. Laster ; C. Isaacson ; E. Perets…
• 关键词：Telomerase inhibition ; Alternative telomere lengthening ; Photon activation therapy
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：141
• 期：1
• 页码：23-34
• 全文大小：887 KB
• 参考文献：1. Adam JF, Biston MC, Joubert A, Charvet AA, Le Bas JF, Esteve F et al (2005) Enhanced delivery of iodine for synchrotron stereotactic radiotherapy by means of intracarotid injection and bloodbrain barrier disruption: quantitative iodine biodistribution studies and associated dosimetry. Int J Radiat Oncol 61:1173-182 CrossRef
  2. Adam JF, Joubert A, Biston MC, Charvet AM, Peoc’h M, Le Bas JF et al (2006) Prolonged survival of Fischer rats bearing F98 glioma after iodine-enhanced synchrotron stereotactic radiotherapy. Int J Radiat Oncol 64:603-11 CrossRef
  3. Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL (2003) Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102:517-20 CrossRef
  4. Aragona M, Maisano R, Panetta S, Giudice A, Morelli M, La Torre I et al (2000) Telomere length maintenance in aging and carcinogenesis. Int J Oncol 17:981-89
  5. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW (2004a) Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 64:3444-451 CrossRef
  6. Bechter OE, Shay JW, Wright WE (2004b) The frequency of homologous recombination in human ALT cells. Cell Cycle 3:547-49 CrossRef
  7. Beisner J, Dong M, Taetz S, Nafee N, Griese EU, Schaefer U et al (2010) Nanoparticle mediated delivery of 2-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Lung Cancer 68:346-54 CrossRef
  8. Biston MC, Joubert A, Adam JF, Elleaume H, Bohic S, Charvet AM et al (2004) Cure of fisher rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays. Cancer Res 64:2317-323 CrossRef
  9. Blagoev KB (2009) Cell proliferation in the presence of telomerase. PLoS One 4:e4622 CrossRef
  10. Bobyk L, Edouard M, Deman P, Vautrin M, Pernet-Gallay K, Delaroche J et al (2013) Photoactivation of gold nanoparticles for glioma treatment. Nanomed Nanotechnol Biol Med 9:1089-097 CrossRef
  11. Ceberg C, Jonsson BA, Prezado Y, Pommer T, Nittby H, Englund E et al (2012) Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation. Phys Med Biol 57:8377-391 CrossRef
  12. Charlton DE, Humm JL (1988) A method of calculating initial DNA strand breakage following the decay of incorporated 125I. Int J Radiat Biol Relat Stud Phys Chem Med 53:353-65 CrossRef
  13. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H et al (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20:6958-968 CrossRef
  14. Delhommeau F, Thierry A, Feneux D, Lauret E, Leclercq E, Courtier MH et al (2002) Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 21:8262-271 CrossRef
  15. Dlaska M, Schoffski P, Bechter OE (2013) Inter-telomeric recombination is present in telomerase-positive human cells. Cell Cycle 12:2084-099 CrossRef
  16. el-Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic age
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Background Telomerase activation and an alternative lengthening of telomeres (ALT) mechanism are two telomere-lengthening cancer cell survival mechanisms elicited by both chemo- and/or radiotherapy. Telomere lengthening interferes with cell lethality and results in the immortalization of cancer cells. To counteract these mechanisms, we developed a drug delivery system (DDS) consisting of a polymeric implant that is inserted directly into tumors. The DDS releases, continuously and gradually, a cationic porphyrin (PdTMPyP4) for >30 days after a single application, and inhibits telomerase activation. Methods The PdTMPyP4 porphyrin is incorporated into a poly(co-glycolic lactic)acid (PLGA) polymer, solidified and cut into small rods. PdTMPyP4 release from the rods was measured spectrophotometrically over time. Uptake of Pd in the DNA of in L428 Hodgkins lymphoma cells was measured by ICP-MS, and telomerase activation by the TRAP assay. The rods were placed into the growth medium of cells whose growth rate was measured for 11 and 19 days. The cylinders were also inserted directly into KHJJ murine mammary tumors borne on the thighs of BALB/c mice and the tumor growth rate measured. Results In vitro, >109Pd atoms were measured in the DNA of each L428 cell and telomerase activity was reduced by ~15?% within 24?h. A one-time application of the rod in the cell medium induced a factor of >5 greater lethality compared to a blank rod or untreated controls. In vivo, a one-time insertion of the rod into tumors resulted in the retardation of the growth rate by factors of 3- compared to untreated controls. Systemic uptake after intratumoral insertion of the rod was negligible. Conclusion The results suggest that the direct intratumoral insertion of a PdTMPyP4-containing polymeric rod would be of benefit as an adjuvant treatment for patients undergoing chemo- or radiotherapy. By preventing the lengthening of telomeres and therefore the unrestricted growth of cancer cells, our DDS will provide a significant therapeutic advantage to these treatments without affecting normal tissues.